NCT07428031

Brief Summary

This study aims to create a registry of patients with hypertrophic cardiomyopathy, a condition characterized by excessive thickening of the heart muscle. This disease can sometimes lead to serious complications. Currently, the prognosis of these patients is mainly determined by clinical and echocardiographic parameters. Detection of myocardial fibrosis using cardiac MRI enables better risk stratification for these patients.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
120mo left

Started Mar 2026

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress2%
Mar 2026Mar 2036

First Submitted

Initial submission to the registry

February 16, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 23, 2026

Completed
6 days until next milestone

Study Start

First participant enrolled

March 1, 2026

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2031

Expected
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2036

Last Updated

February 23, 2026

Status Verified

February 1, 2026

Enrollment Period

5 years

First QC Date

February 16, 2026

Last Update Submit

February 16, 2026

Conditions

CardiomyopathyHypertrophic Cardiomyopathies

Keywords

Cardiac Magnetic ResonanceCardiomyopathy

Outcome Measures

Primary Outcomes (1)

  • To build a score using the "LGE granularity" concept for all-cause mortality prediction in HCM patients.

    All-cause mortality using the electronic French National Registry of Death (Institut National de la Statistique et des Etudes Economiques, INSEE registry).

    From Baseline to 5 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study will include all consecutive patients with a HCM referred for CMR assessment.

You may qualify if:

  • Age ≥ 18 years
  • Ability to provide informed consent
  • HCM diagnosis referred for CMR assessment.

You may not qualify if:

  • Patients unable to provide informed consent,
  • Patients with a history of ischemic cardiomyopathy or myocarditis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

CardiomyopathiesCardiomyopathy, Hypertrophic

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesAortic Stenosis, SubvalvularAortic Valve StenosisAortic Valve DiseaseHeart Valve Diseases

Central Study Contacts

Théo PEZEL, Dr

CONTACT

+33 6 68 72 24 89theo.pezel@aphp.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 16, 2026

First Posted

February 23, 2026

Study Start

March 1, 2026

Primary Completion (Estimated)

March 1, 2031

Study Completion (Estimated)

March 1, 2036

Last Updated

February 23, 2026

Record last verified: 2026-02